Implanet SA (IM11) Price & Analysis

― Followers

IM11 Stock Chart & Stats

€0.28

>-€0.01(-1.68%)

At close: Jan 08 4:00 PM EST

€0.28

>-€0.01(-1.68%)

Day’s Range― - ―

52-Week Range€0.15 - €0.42

Previous CloseN/A

Volume0.00

Average Volume (3M)0.00

Market Cap

€24.42M

Enterprise Value€28.91

Total Cash (Recent Filing)€3.01M

Total Debt (Recent Filing)€5.92M

Price to Earnings (P/E)―

Beta-0.34

Next Earnings

Sep 15, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.03

Shares Outstanding143,818,970

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio0.35

Price to Book (P/B)70.59

Price to Sales (P/S)2.29

P/FCF Ratio-13.27

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Strong Revenue ReboundThe substantial revenue rebound indicates stronger demand for Implanet’s orthopedic and spine solutions. If sustained, higher procedure-related sales can improve operating leverage and support the company’s path toward scale.

Improving Gross MarginThe margin expansion suggests a more favorable product mix, pricing, manufacturing profile, or commercial execution. Sustained gross-margin improvement would provide more resources to fund operations and reduce the earnings gap.

Cash Flow Trend ImprovingAlthough operating cash flow remains negative, the sharp improvement shows progress in cash conversion. Continued revenue growth and better margins could help narrow the funding requirement and eventually support internally financed operations.

Bears Say

Persistent Net LossesPersistent losses show that revenue growth and gross-margin gains have not yet translated into a viable earnings model. Continued deficits could limit investment capacity and require further financing before profitability is achieved.

Highly Leveraged Balance SheetVery high leverage and minimal equity provide little protection against operating setbacks. The thin capital cushion increases refinancing and solvency risk, while debt obligations may constrain investment in products, sales channels, and growth.

Ongoing External Funding NeedNegative operating and free cash flow indicate that the business is not yet self-funding despite its revenue rebound. Reliance on external capital may dilute shareholders, increase leverage, or restrict growth if financing becomes difficult.

IM11 FAQ

What was Implanet SA’s price range in the past 12 months?

Implanet SA lowest stock price was €0.15 and its highest was €0.42 in the past 12 months.

What is Implanet SA’s market cap?

Implanet SA’s market cap is €24.42M.

When is Implanet SA’s upcoming earnings report date?

Implanet SA’s upcoming earnings report date is Sep 15, 2026 which is in 2 days.

How were Implanet SA’s earnings last quarter?

Implanet SA released its earnings results on Feb 24, 2026. The company reported -€0.017 earnings per share for the quarter.

Is Implanet SA overvalued?

According to Wall Street analysts Implanet SA’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Implanet SA pay dividends?

Implanet SA does not currently pay dividends.

What is Implanet SA’s EPS estimate?

Implanet SA’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Implanet SA have?

Implanet SA has 143,818,970 shares outstanding.

What happened to Implanet SA’s price movement after its last earnings report?

Implanet SA reported an EPS of -€0.017 in its last earnings report. Following the earnings report the stock price went down -3.723%.

Which hedge fund is a major shareholder of Implanet SA?

Currently, no hedge funds are holding shares in DE:IM11

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Implanet SA

Implanet S.A., together with its associated companies, is dedicated to the research, development, manufacturing, and commercialization of spinal and orthopedic medical implants. The firm's product portfolio addresses both spinal and knee needs. Its spinal offerings encompass various posterior fixation systems, including the Jazz PF, Jazz Evo, Jazz Cap SP, Jazz Passer, Jazz Lock, Jazz Claw, Jazz Frame, and ISS-Jazz Screw lines. Furthermore, Implanet S.A. provides knee prostheses, which are marketed under the Madison brand. The company has a significant strategic alliance with Shanghai Sanyou Medical Co, Ltd. Established in 2006, Implanet S.A. operates from its headquarters in Martillac, France.